Printer Friendly

Browse Clinical trials topic

Articles

1-300 out of 600 article(s) nextnext page
Title Author Type Date Words
Bio2 Technologies Inc wins US FDA approval to evaluate Vitrium as a cervical interbody fusion device under IDE clinical study. Nov 14, 2018 194
Bio2 Technologies Inc wins US FDA approval to evaluate Vitrium as a cervical interbody fusion device under IDE clinical study. Nov 14, 2018 198
PolyPid passes US FDA clearance to launch clinical trial of D-PLEX[100] for the prevention of sternal wound infection. Nov 13, 2018 233
Clinical Trial Offers Hope for HIV Cure. Nov 13, 2018 150
Aravive: AVB-S6-500 met endpoints in Phase 1 clinical trial. Nov 13, 2018 375
Statistical Consultations And Analyzes In Clinical Research (sweden-vnersborg: Statistical Services). Nov 13, 2018 134
PolyPid passes US FDA clearance to launch clinical trial of D-PLEX[100] for the prevention of sternal wound infection. Clinical report Nov 13, 2018 237
PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer. Nov 12, 2018 676
Concert Pharmaceuticals reports 'positive' CTP-543 results in Phase 2a trial. Nov 12, 2018 370
Akcea, Ionis say Phase 2 study in patients with elevated Lp(a) met endpoints. Clinical report Nov 12, 2018 287
Ophthotech announces results from Phase 2a safety trial of Zimura. Financial report Nov 12, 2018 749
Madrigal Pharmaceuticals presents Phase 2 results for MGL-3196 in NASH. Nov 12, 2018 113
United States : Dr. Jill Biden, National Minority Quality Forum, Global Sponsors and CROs Discuss the Future of Healthcare and Clinical Research at Medidata NEXT NYC 2018. Nov 12, 2018 278
United States : PharmaCyte Biotech Selects Medpace as CRO for Its Clinical Trial in Pancreatic Cancer. Nov 12, 2018 494
Visterra commences VIS649 phase one clinical study. Clinical report Nov 12, 2018 195
Visterra commences VIS649 phase one clinical study. Clinical report Nov 12, 2018 191
Monitoring Clinical Studies. Clinical report Nov 11, 2018 281
Eidos Therapeutics announces positive Phase 2 data for AG10. Nov 11, 2018 308
Fate Therapeutics announces dose-escalation clinical data of FATE-NK100. Nov 11, 2018 512
Enyo Pharma Completes Phase Ib with Its FXR Agonist EYP001 and the Start of Phase II Studies in Two Indications, NASH and HBV. Nov 9, 2018 723
Alpine says 'on track' to initiate human clinical trials of ALPN-202 in 4Q19. Nov 9, 2018 380
Gilead presents Phase 2 data on investigational FXR agonist GS-9674. Nov 9, 2018 553
Spring Bank Pharmaceuticals presents additional Phase 2 ACHIEVE results at AASLD. Nov 9, 2018 293
Mirati Therapeutics presents data from Phase 2 trial of sitravatinib/nivolumab. Nov 9, 2018 262
Mirati Therapeutics presents preliminary data from Phase 2 trial of sitravatinib. Nov 9, 2018 194
Mirati Therapeutics presents data from Phase 2 trial of mocetinostat combination. Nov 9, 2018 215
X4 Pharmaceuticals Presents Clinical Data Demonstrating Single Agent X4P-001-IO Enhances Tumor Immunity through CXCR4 Antagonism. Nov 9, 2018 627
Sensei Biotherapeutics Presents Clinical Trial Data Demonstrating SNS-301 Induces Rapid and Robust Antigen-specific Immune Responses. Nov 9, 2018 743
Reagents, Control And Consumables For Analyzers Of A Clinical Diagnostic Laboratory, Diagnostic Kits For General Clinical Research Of A Health Care Institution 4th City Childrens Clinical Polyclinic. Nov 8, 2018 149
Themis Bioscience Publishes Compelling Phase 2 Results for Lead Vaccine Candidate against Chikungunya Fever in The Lancet. Nov 8, 2018 488
InflaRx completes enrollment in IFX-1 Phase IIb clinical trial. Clinical report Nov 8, 2018 157
Urovant Sciences completes patient enrollment in vibegron Phase 3 pivotal trial. Clinical report Nov 8, 2018 166
BeiGene initiates head-to-head Phase 3 Zanubrutinib trial. Nov 7, 2018 267
Rocket Pharmaceuticals announces FDA clearance of IND application for RP-L102. Nov 7, 2018 130
Endo announces 'positive' results from Phase 3 studies of CCH. Nov 7, 2018 118
Aridis Pharmaceuticals' AR-301 Phase 1/2a data featured in publication. Nov 7, 2018 179
OncoSec doses first patient in KEYNOTE-890 Phase 2 clinical trial. Nov 7, 2018 117
BD announces clinical trial data for Lutonix IDE level 1 for BTK indication. Clinical report Nov 7, 2018 236
Voyager told by FDA Phase 2 trial is an early phase exploratory study. Nov 7, 2018 186
Genkyotex's GKT831 succeeds in a phase two trial in primary biliary cholangitis. Nov 7, 2018 174
Bristol-Myers Squibb establishes clinical trial collaboration with Infinity Pharmaceuticals. Nov 7, 2018 207
Genkyotex's GKT831 succeeds in a phase two trial in primary biliary cholangitis. Nov 7, 2018 170
Bristol-Myers Squibb establishes clinical trial collaboration with Infinity Pharmaceuticals. Nov 7, 2018 203
Purdue Pharma announces enrolment of first patient Phase 1 investigator-initiated clinical trial of tinostamustine treatment for glioblastoma. Nov 6, 2018 257
FLX Bio Inks Clinical Trial Collaboration Agreement with Merck for Ongoing Phase 1/2 Study of FLX475. Nov 6, 2018 380
Purdue Pharma announces enrolment of first patient Phase 1 investigator-initiated clinical trial of tinostamustine treatment for glioblastoma. Nov 6, 2018 253
Oncobiologics advances ONS-5010 into wet AMD clinical trial. Nov 6, 2018 154
United States : Phase 1b/2 Data of Durvalumab Plus Danvatirsen Presented at European Society for Medical Oncology. Nov 6, 2018 403
Acesion Pharma reports positive results from Phase 1 clinical trial of lead compound in cardioversion, AP30663. Nov 5, 2018 234
Acesion Pharma reports positive results from Phase 1 clinical trial of lead compound in cardioversion, AP30663. Nov 5, 2018 230
Opiant Pharmaceuticals announces LPLV for Phase 2 OPNT001 trial. Clinical report Nov 5, 2018 111
Clearside Biomedical says Sapphire Phase 3 study did not meet primary endpoint. Nov 5, 2018 163
CohBar: Phase 1 CB4211 study 'temporarily suspended' to address site reactions. Nov 5, 2018 236
United States : Physician at Hackensack University Medical Center Leads the first U.S. Clinical Trial of a Promising New Drug to TreatCharcot-Marie-Tooth Disease. Nov 5, 2018 430
Verona Pharma completes patient enrolment for phase two trial of RPL554. Nov 5, 2018 256
Bavarian Nordic announces first patent dosed and initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers. Nov 5, 2018 421
Verona Pharma completes patient enrolment for phase two trial of RPL554. Nov 5, 2018 252
Bavarian Nordic announces first patent dosed and initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers. Nov 5, 2018 417
Lipocine Inc concludes enrolment under the ambulatory blood pressure clinical study of TLANDO. Clinical report Nov 2, 2018 217
Lipocine Inc concludes enrolment under the ambulatory blood pressure clinical study of TLANDO. Clinical report Nov 2, 2018 213
Cyclacel, MD Anderson enter into clinical studies partnership. Nov 2, 2018 232
Delayed Start Protocol with Gonadotropin-releasing Hormone Antagonist in Poor Responders Undergoing In Vitro Fertilization: A Randomized, Double-blinded, Clinical Trial. Zarei, Afsoon; Parsanezhad, Mohammad Ebrahim; Kutenaei, Maryam Azizi; Jahromi, Bahia Namavar; Bakhsh Nov 1, 2018 4110
Sublingual Immunotherapy Tablets Relieve Symptoms in Adults with Allergic Rhinitis: A Meta-analysis of Randomized Clinical Trials. Li, Yi; Yu, Shi-Yuan; Tang, Rui; Zhao, Zuo-Tao; Sun, Jin-Lyu Report Nov 1, 2018 4235
Comment to 'Recurrent Glioblastoma Treated with Recombinant Poliovirus'. Wang, Peng; Chen, Guang-Zhong Report Nov 1, 2018 708
US FDA grants approval to Sandoz's Hyrimoz. Nov 1, 2018 136
US FDA grants approval to Sandoz's Hyrimoz. Nov 1, 2018 132
Senhwa Biosciences wins US FDA's approval for Silmitasertib's IND for the treatment of basal cell carcinoma. Nov 1, 2018 277
Senhwa Biosciences wins US FDA's approval for Silmitasertib's IND for the treatment of basal cell carcinoma. Nov 1, 2018 273
Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China. Nov 1, 2018 185
Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China. Nov 1, 2018 181
Constellation Pharmaceuticals receives fast track designation for CPI-0610. Nov 1, 2018 156
Novan data from SB206 Phase 2 trial published in Journal of Drugs in Dermatology. Nov 1, 2018 158
Karyopharm to present results of clinical studies investigating selinexor. Clinical report Nov 1, 2018 346
Histogenics, FDA continue to discuss NeoCart Phase 3 data, regulatory pathway. Nov 1, 2018 126
Comparison of frequency of post-obturation pain of single versus multiple visit root canal treatment of necrotic teeth with infected root canals. A Randomized Controlled Trial. Clinical report Oct 31, 2018 3113
Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CTLA-4 Monoclonal Antibody. Oct 31, 2018 286
Horizon Pharma Presents Results of 48 Week Off-Therapy Follow-Up to the Phase 2 Trial of Teprotumumab. Oct 31, 2018 680
Aura Biosciences Presents Updated Phase 1b/2 Clinical Data for AU-011. Oct 31, 2018 689
Acadia reports Phase 2 CLARITY trial in MDD met primary endpoint. Oct 31, 2018 252
Tonix Pharmaceuticals announces design for Phase 3 study of Tonmya for PTSD. Oct 31, 2018 256
Savara completes target enrollment for OPTIMA trial. Oct 31, 2018 105
CStone doses first patient with solid tumour under Phase I study of MEK inhibitor CS3006. Oct 30, 2018 246
CStone doses first patient with solid tumour under Phase I study of MEK inhibitor CS3006. Oct 30, 2018 242
Humacyte Starts Phase II Vascular Trauma Trial. Oct 30, 2018 504
Anavex announces first patient enrolled in Phase 2 ANAVEX2-73 study for PDD. Clinical report Oct 30, 2018 112
Mustang Bio announces initiation of Phase 1 in HER2-positive breast cancer. Oct 30, 2018 228
CymaBay initiates Phase 3 ENHANCE trial for treatment of PBC. Oct 30, 2018 117
Japan : Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at Clinical Trials on Alzheimers Disease (CTAD). Oct 30, 2018 258
Japan : Eisai Presents New Data on Lemborexant for Treatment of Irregular Sleep-wake Rhythm Disorder in Patients With Alzheimers Disease at the 11th Clinical Trials in Alzheimers Disease Conference. Conference news Oct 30, 2018 709
Japan : Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimers Disease at the 2018 Clinical Trials on Alzheimers Disease (Ctad) Conference. Clinical report Oct 30, 2018 335
Generex Biotechnology Makes IND Filing for a Phase II Clinical Trial of AE37 in Combination with Pembrolizumab (Keytruda) for the Treatment of Triple-Negative Breast Cancer. Oct 30, 2018 440
Bristol-Myers Squibb doses first patient in clinical trial of BMS-986179. Oct 29, 2018 195
Daiichi Sankyo, Merck and Pfizer sign clinical trial collaboration agreement. Oct 29, 2018 262
Nordic Nanovector selects first US clinical trial site for Betalutin Lymphoma drug. Oct 29, 2018 260
Bristol-Myers Squibb doses first patient in clinical trial of BMS-986179. Oct 29, 2018 191
Daiichi Sankyo, Merck and Pfizer sign clinical trial collaboration agreement. Oct 29, 2018 258
Nordic Nanovector selects first US clinical trial site for Betalutin Lymphoma drug. Oct 29, 2018 256
AC Immune's partner Life molecular presents data from 18F-PI-2620 clinical study. Clinical report Oct 29, 2018 109
Melinta Therapeutics announces results from Phase 3 Baxdela trial. Oct 29, 2018 255
Biogen and Eisai Announce Presentation of Detailed Analyses from the Phase 1b Long-Term Extension Study of Aducanumab at CTAD. Oct 29, 2018 1237
GenSight Biologics Enrolls First Subject in First-in-man PIONEER Phase I/II Clinical Trial of GS030 Combining Gene Therapy and Optogenetics for the Treatment of Retinitis Pigmentosa. Oct 29, 2018 885
Spark Therapeutics presents analyses from Phase 3 trial of Luxturna. Oct 29, 2018 219
Esperion announces positive top-line results from Phase 3 Bempedoic Acid study. Clinical report Oct 28, 2018 324
United States : Demonstrated a Significant Improvement in Progression-Free Survival (PFS) Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma. Oct 27, 2018 212
Jit Automated Clinical Trial Pharmacy Solution. Oct 27, 2018 505
Nordic opens first clinical site in the US for the enrollment of patients under the pivotal PARADIGME trial. Oct 26, 2018 268
Roche's Xofluza granted FDA approval. Oct 26, 2018 175
Biogen, Eisai present Phase 1b aducanumab data at CTAD. Oct 26, 2018 158
Eisai and Biogen Announce Presentation of Additional Data From the Phase II Clinical Trial of BAN2401 in Early Alzheimer's Disease. Clinical report Oct 26, 2018 2126
Novaliq Touts Positive Topline Results for Its SEECASE Phase 2 Trial of NOV03 for the Treatment of Patients with Dry Eye Disease. Oct 26, 2018 284
Consumables For Hematological And Clinical Trials. Oct 26, 2018 162
Cortexyme Touts Phase 1 Data Demonstrating COR388 is Safe and Well Tolerated in Healthy Older Volunteers and Alzheimer's Patients. Oct 26, 2018 922
Oyster Point Touts Positive Results from Two Separate Phase 2b Clinical Trials of the company's Investigational Treatments for Dry Eye Disease. Oct 26, 2018 241
BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. Conference news Oct 26, 2018 366
BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. Conference news Oct 26, 2018 367
BioArctic presents additional BAN2401 phase 2b study results in early Alzheimer's disease at the 2018 CTAD conference in Barcelona. Conference news Oct 26, 2018 362
Nordic opens first clinical site in the US for the enrollment of patients under the pivotal PARADIGME trial. Oct 26, 2018 272
Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met. Oct 25, 2018 460
Green Valley Pharmaceutical updates Phase 3 clinical trial of GV-971 at 11th Clinical Trials on Alzheimer's Disease Conference in Barcelona, Spain. Conference news Oct 25, 2018 262
Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met. Oct 25, 2018 461
Orion and Bayer announce completion of phase III trial of darolutamide; primary end point met. Oct 25, 2018 456
Green Valley Pharmaceutical updates Phase 3 clinical trial of GV-971 at 11th Clinical Trials on Alzheimer's Disease Conference in Barcelona, Spain. Conference news Oct 25, 2018 258
Kadmon initiates Phase 2 KD025 trial in cGVHD. Oct 25, 2018 168
Bristol-Myers doses first subject in Phase 1 trial using Halozyme's Enhanze. Oct 25, 2018 153
Inovio announces results from Pennvax-GP Phase 1 study. Oct 25, 2018 131
FibroGen presents two phase 3 study results of Roxadustat in CKD treatment. Oct 25, 2018 206
Revlimid Demonstrated a Significant Improvement in Progression-Free Survival Compared with Observation in a Randomized Study in Patients with Smoldering Multiple Myeloma. Oct 25, 2018 181
Japan : Eisai to present latest data on Alzheimers Disease/Dementia Pipeline at 11th Clinical Trials on Alzheimers Disease conference. Conference news Oct 25, 2018 383
Switzerland : Roche announces FDA approval of Xofluza (baloxavir marboxil) for influenza. Oct 25, 2018 300
United States : Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting. Oct 25, 2018 156
Myovant Sciences: Enrollment complete in Phase 3 HERO trial of relugolix. Oct 24, 2018 128
Neurotrope updates Phase 2 data of Alzheimer's candidate Bryostatin-1. Oct 24, 2018 199
Genentech announces FDA approval of Xofluza for influenza. Oct 24, 2018 201
Pancreatology Publishes Results of the PANOVA Phase 2 Pilot Trial in Advanced Pancreatic Cancer Suggesting Improved Survival of Patients Treated with Tumor Treating Fields. Clinical report Oct 24, 2018 544
Provision Of Placebo And Minipress Drugs; Receipt, Packaging, Labeling, Storage, And Shipments Of Placebo Or Minipress For Clinical Trial "prazodream". Oct 24, 2018 181
Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients. Oct 23, 2018 165
Lynparza phase III trial indicates decreased risk of disease progression or death in BRCA-mutated ovarian cancer patients. Oct 23, 2018 161
Solo-1 Phase III Trial Demonstrates Lynparza Maintenance Therapy Cut the Risk of Disease Progression or Death by 70% in Patients with Newly-Diagnosed, Advanced BRCA-Mutated Ovarian Cancer. Oct 23, 2018 143
Deciphera initiates Phase 1b/2 clinical trial of rebastinib. Oct 23, 2018 173
iCAD announces new clinical data on the Xoft Electronic Brachytherapy System. Oct 23, 2018 166
Amcure Presents First Clinical Data for Lead Compound AMC303 at ESMO 2018 Congress. Oct 23, 2018 492
Cantargia presents positive phase I trial CANFOUR clinical data with lead candidate CAN04 at ESMO 2018. Oct 22, 2018 296
Cantargia presents positive phase I trial CANFOUR clinical data with lead candidate CAN04 at ESMO 2018. Oct 22, 2018 300
Neon Therapeutics presents Phase 1b data on NEO-PV01 vaccine. Oct 22, 2018 188
Oncolytics: Pelareorep more than doubles OS at recommended Phase 2 dose. Oct 22, 2018 218
NuCana presents data from Phase 1 NUC-3373 study at ESMO. Oct 22, 2018 141
Novocure announces publication of results of PANOVA phase 2 pilot trial. Clinical report Oct 22, 2018 380
Zai Lab announces approval of Zejula for patients with relapsed ovarian cancer. Oct 22, 2018 237
Flexion to present data from Phase 2 Zilretta study at ACR. Oct 22, 2018 206
Ionis Pharmaceuticals presents Phase 1b/2 data of danvatirsen. Oct 22, 2018 194
Ctn Data Statistics And Clinical Trial Support Center (dsc5). Oct 21, 2018 110
Tesaro presents Phase 1 GARNET data of TSR-042 in MSI-H endometrial cancer. Oct 21, 2018 648
Gilead, Galapagos NV announced data from Phase 3 FINCH2 trial of filgotinib. Oct 21, 2018 308
G1 presents additional data from randomized Phase 2 trial in first-line SCLC. Oct 21, 2018 161
United States : Dupixent (Dupilumab) Showed Positive Topline Results in Two Phase 3 Trials of Patients With Chronic Rhinosinusitis With Nasal Polyps. Oct 20, 2018 197
France : Centre Georges Franois Leclerc Presents the Detailed Results of the First Two Stages of its Clinical Study in Lung Cancer at the EANM Congress. Clinical report Oct 20, 2018 172
Spain : PharmaMar will present at ESMO results of the phase III CORAIL study with lurbinectedin in platinum-resistant Ovarian Cancer. Oct 20, 2018 169
Innovent Biologics Inc treats first patient in phase I clinical trial of anti-CTLA-4 monoclonal antibody (IBI310). Oct 19, 2018 208
Innovent Biologics Inc treats first patient in phase I clinical trial of anti-CTLA-4 monoclonal antibody (IBI310). Oct 19, 2018 204
Clovis reports initial data from Phase 2 TRITON2 clinical trial of Rubraca. Oct 19, 2018 196
Merrimack announces termination of Phase 2 SHERLOC study. Clinical report Oct 19, 2018 184
Deciphera reports preliminary results of Phase 1 clinical study of DCC-2618. Oct 19, 2018 567
Novartis: Phase II Geometry data shows ORR of 72%, 39.1% in study. Oct 19, 2018 214
Incyte: Phase II Geometry data shows ORR of 72%, 39.1% in study. Oct 19, 2018 162
Rodin Therapeutics Launches Clinical Trial of Neuroimaging Tool for Measurement of Synaptic Density. Oct 19, 2018 294
Aelix Therapeutics, Gilead Sciences Enter into a Clinical Research Collaboration Agreement to Evaluate a Therapeutic Vaccine and TLR7 Agonist Regimen for HIV Cure. Clinical report Oct 19, 2018 450
GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy. Oct 19, 2018 595
Lab-on-skin: Lab-on-skin: A wearable medical device for improved clinical trial monitoring. Oct 19, 2018 326
Imoted: Imoted platform built to improve clinical trial outcomes. Oct 19, 2018 420
Mood: Feasibility study for the introduction into pre-clinical study domain of the first-of-a-kind multi organ on device (mood) technology. Oct 19, 2018 330
Five Prime Therapeutics Initiates Patient Dosing in The Dose Exploration Cohort of Its Phase 1 Trial of Novel First-in-class B7-H4 Antibody FPA150. Oct 18, 2018 441
Selecta Biosciences reports patient death in Phase 1 SEL-403 trial. Oct 18, 2018 401
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference. Conference news Oct 18, 2018 1232
First Patient Dosed in a Phase 1/2 Trial of Transgene's Oncolytic Virus TG6002 Administered Intravenously in Patients with Advanced Gastrointestinal Tumors. Oct 18, 2018 714
Natera and Neon Therapeutics collaborate on cancer vaccine trial. Oct 18, 2018 127
Natera, Neon Therapeutics announce clinical trial collaboration for NEO-PV-01. Oct 18, 2018 166
Quotient Sciences Constructs Early-Phase Formulation and Manufacturing Facility in US. Oct 17, 2018 287
Auris Medical reports Phase 1 clinical trial results for intranasal betahistine. Oct 17, 2018 140
Aslan Pharmaceuticals enrolls first subject in Phase 1 study for ASLAN004. Oct 17, 2018 177
Cellenkos to launch phase I clinical trial of CK0801 in patients with Guillain-BarrA(c) Syndrome (GBS) following US FDA clearance. Oct 17, 2018 250
Alphamab Oncology announces US FDA approval for cancer therapy KN026. Oct 17, 2018 220
CStone passes US FDA IND approval for PD-L1 antibody, CS1001. Oct 17, 2018 200
Cellenkos to launch phase I clinical trial of CK0801 in patients with Guillain-BarrA(c) Syndrome (GBS) following US FDA clearance. Oct 17, 2018 246
Alphamab Oncology announces US FDA approval for cancer therapy KN026. Oct 17, 2018 216
CStone passes US FDA IND approval for PD-L1 antibody, CS1001. Oct 17, 2018 196
ResTORbio announces additional data from RTB101 Phase 2b clinical trial. Oct 16, 2018 267
Five Prime initiates patient dosing in dose exploration cohort of Phase 1 trial. Oct 16, 2018 258
Celcuity, Puma Biotechnology and West Cancer Center to conduct Phase 2 trial. Oct 16, 2018 310
United Kingdom : Supply of Investigational Medicinal Products for clinical trials in the event of a no-deal. Oct 16, 2018 305
United States : Bipartisan Senators to NIH: Improve Racial, Ethnic Minority Representation in Clinical Trials. Oct 16, 2018 172
United States : Cortez Masto, Colleagues Call on Nih to Improve Racial, Ethnic Minority Representation in Clinical Trials. Oct 16, 2018 218
Mereo BioPharma Group completes patient enrolment for phase 2b clinical trial of BPS-804. Oct 16, 2018 158
MaaT Pharma doses first patient in phase two clinical trial of MaaT013. Clinical report Oct 16, 2018 218
Reflexion Health's first randomised controlled trial in virtual physical therapy excels against traditional approach. Oct 16, 2018 276
Mereo BioPharma Group completes patient enrolment for phase 2b clinical trial of BPS-804. Oct 16, 2018 154
MaaT Pharma doses first patient in phase two clinical trial of MaaT013. Clinical report Oct 16, 2018 214
Reflexion Health's first randomised controlled trial in virtual physical therapy excels against traditional approach. Oct 16, 2018 272
Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1 Study of ARO-ANG3. Oct 16, 2018 245
Peptilogics Receives Australian Regulatory Approval to Initiate First-in-Human Safety Study for Therapeutic Peptide PLG0206. Oct 16, 2018 447
Electronic 'Smart' Label for Clinical Trials. Oct 15, 2018 195
Innovent to launch clinical trials of the combination therapy of IBI308 and IBI305 in patients with NSCLC & HCC in China. Oct 15, 2018 284
Innovent to launch clinical trials of the combination therapy of IBI308 and IBI305 in patients with NSCLC & HCC in China. Oct 15, 2018 280
Genentech says Phase III KATHERINE study met primary endpoint. Oct 15, 2018 202
Arrowhead files for regulatory clearance to begin Phase 1 study of ARO-ANG3. Oct 15, 2018 165
OncoSec initiates Phase 2 cllinical trial of Tavo with Merck's Keytruda. Oct 15, 2018 123
Krystal Biotech announces interim results from Phase 1/2 trial of KB103. Oct 15, 2018 554
Savara completes enrollment of IMPALA Phase 3 study. Oct 15, 2018 110
Aimmune Therapeutics announces initiation of Phase 2 study of AR101. Oct 15, 2018 243
United States : Arena Pharmaceuticals Presented Phase 2 Clinical Data for Etrasimod in Ulcerative Colitis at the American College of Gastroenterology Annual Meeting. Oct 15, 2018 150
United States : Arena Pharmaceuticals Reports Positive Long-Term Data from the Ongoing Open-Label Extension of the Phase 2 Trial Evaluating Ralinepag for Treatment of Pulmonary Arterial Hypertension. Clinical report Oct 15, 2018 592
Israel : Teva Presents 25-year Safety Data from Longest Continuous Trial of COPAXONE (glatiramer acetate injection) for the Treatment of Relapsing Forms of Multiple Sclerosis. Oct 15, 2018 389
ISCO Doses Tenth Patient In Parkinson's Disease Clinical Trial. Oct 15, 2018 390
ISCO Doses Tenth Patient In Parkinson's Disease Clinical Trial. Oct 15, 2018 389
Cooper team helping battle rare genetic disorder. Vecchione, Anthony Oct 15, 2018 500
Nofel Izz raising USD 30 mn to democratise clinical research and trials. Oct 12, 2018 834
MaxCyte doses first patient in MCY-M11 US phase I dose-escalation clinical trial. Oct 12, 2018 208
MaxCyte doses first patient in MCY-M11 US phase I dose-escalation clinical trial. Oct 12, 2018 204
I-Mab Biopharma treats the first ulcerative colitis patient in China under its phase II clinical trial of TJ301. Oct 12, 2018 235
First Patient Dosed in Phase 2 Clinical Trial of MaaT Pharma Lead Product MaaT013, a First-in-class Biotherapeutic to Treat Acute GvHD. Oct 12, 2018 450
BeiGene presents updated Phase 1 data on zanubrutinib. Oct 12, 2018 201
Singapore : Winners of Newtrition Asia Research Grant 2018 to address pressing health concerns in Asia with new clinical studies. Clinical report Oct 12, 2018 585
Clinical Research Administrative Management Service. Oct 12, 2018 109
International Clinical Trial Utilises Personal Genome Diagnostics' Liquid Biopsy Assay to Enroll Patients based on POLE/POLD1 status as a Predictor of Response to Immunotherapy. Oct 11, 2018 271
First clinical trial of Alzheimer's disease treatment starts at The National Institute for Health Research University College London Hospitals Clinical Research Facility. Oct 11, 2018 212
First clinical trial of Alzheimer's disease treatment starts at The National Institute for Health Research University College London Hospitals Clinical Research Facility. Oct 11, 2018 208
Progenics advances prostrate cancer treatment to phase 2 after FDA discussions. Oct 11, 2018 226
BioPharmX initiates Phase 2b trial of BPX-04 for rosacea. Oct 11, 2018 120
Australia : Pharmaxis Releases Positive Results of Phase 1 Clinical Trial for LOXL2 Inhibitor Compound. Oct 11, 2018 252
Crispr Therapeutics, Vertex announce FDA lifts hold for CTX001, accepts IND. Oct 10, 2018 127
Constellation Pharmaceuticals expands Phase 2 study of CPI-0610. Oct 10, 2018 258
General Committee to review Sisi's objections to clinical trials draft law. Oct 10, 2018 556
NeuroVive Pharmaceutical announces receipt of KL1333 clinical trial regulatory approval from MHRA in UK. Oct 10, 2018 238
NeuroVive Pharmaceutical announces receipt of KL1333 clinical trial regulatory approval from MHRA in UK. Oct 10, 2018 234
Symphony Clinical Research earns recertification. Oct 10, 2018 178
TapImmune receives DoD grant for TPIV110 phase 2 study to treat breast cancer. Oct 10, 2018 199
Motus GI presented 'positive' clinical data on Pure-Vu System. Clinical report Oct 10, 2018 246
Revolution Medicines: First Patient Dosed with RMC-4630 in Phase 1 Clinical Study in Patients with Advanced Solid Tumors. Oct 10, 2018 552
Yisheng Biopharma wins China FDA approval to commence PIKA rabies vaccine clinical study in Asia. Oct 9, 2018 206
Yisheng Biopharma wins China FDA approval to commence PIKA rabies vaccine clinical study in Asia. Oct 9, 2018 202
Cavion Touts Promising Phase 2 Data for Essential Tremor in T-CALM Proof-of-Concept Study. Oct 9, 2018 863
G1 Therapeutics announces new data from Phase 2 trilaciclib trial at ESMO. Oct 9, 2018 120
Bellerophon provides update on Phase 2b iNO-PF study. Clinical report Oct 9, 2018 254
Sermonix Pharmaceuticals launches Phase 2 trial to evaluate oral lasofoxifene. Clinical report Oct 9, 2018 123
Nymox: Gleason grade progression reduced by 81% in FT Phase IIb trial. Oct 9, 2018 310
Parliament to review controversial clinical trials draft law. Oct 9, 2018 156
Exelixis Initiates Phase 3 Pivotal Trial of Cabozantinib in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy. Oct 9, 2018 537
Coordination Pharmaceuticals Inc wins US FDA approval to study the first NCP-based product CPI-100 in clinical trials. Oct 8, 2018 219
Coordination Pharmaceuticals Inc wins US FDA approval to study the first NCP-based product CPI-100 in clinical trials. Oct 8, 2018 215
Audentes Therapeutics Touts New Positive Interim Data from ASPIRO, the Phase 1/2 Clinical Trial of AT132 in Patients with X-linked Myotubular Myopathy, at 23rd International Annual Congress of the World Muscle Society. Oct 8, 2018 751
BerGenBio Enters Second Stage of Phase II Trial with Selective AXL Inhibitor bemcentinib in Combination with US Merck's Keytruda in Patients with Advanced NSCLC. Oct 8, 2018 587
Bausch Health's BRYHALI Lotion, 0.01% receives tentative FDA approval. Oct 8, 2018 119
BioXcel Therapeutics submits IND application for BXCL701. Oct 8, 2018 156
Cocrystal Pharma announces clinical trial agreement for CC-31244. Oct 8, 2018 204
FDA puts Affimed N.V.'s AFM11 phase 1 program on hold following death of patient. Oct 8, 2018 212
Affimed N.V. places AFM11 Phase 1 program on clinical hold. Oct 8, 2018 206
Consumables For Hematological And Clinical Trials. Oct 8, 2018 161
Blueprint Medicines Releases Updated Data from Phase 1 ARROW Clinical Trial of BLU-667 in Advanced RET-Altered Medullary and Papillary Thyroid Cancers. Oct 8, 2018 1406
FDA Grants Coordination Pharmaceuticals IND Approval for CPI-100, a Novel Antitumor Nanomedicine. Oct 8, 2018 145
Web-based service targets clinical trial sponsors. Oct 8, 2018 695
Blueprint Medicines announces updated data from Phase 1 ARROW clinical trial. Oct 7, 2018 595
United States : Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma. Financial report Oct 6, 2018 716
Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration. Oct 5, 2018 518
Alnylam Pharmaceuticals files clinical trial authorisation application to start phase 1/2 trial of ALN-AAT02. Oct 5, 2018 246
Spinal Singularity earns USD1.5m NIH Phase II SBIR Grant. Oct 5, 2018 185
Alnylam Pharmaceuticals files clinical trial authorisation application to start phase 1/2 trial of ALN-AAT02. Oct 5, 2018 242
Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration. Oct 5, 2018 560
Alnylam Reports Updated Positive Results from Phase 1/2 Study of Lumasiran in Patients with Primary Hyperoxaluria Type 1. Clinical report Oct 5, 2018 1181
Merck Releases Week 96 Data from Pivotal Phase 3 DRIVE-AHEAD Study Evaluating Delstrigo for the Treatment of HIV-1 in Treatment-NaA-ve Patients. Oct 5, 2018 798
Allergan launches two global clinical research programs for brazikumab. Oct 5, 2018 143
XBiotech completes enrollment of phase 2 bermekimab study. Clinical report Oct 5, 2018 112
PureTech's Vedanta reports successful Phase 1a/1b trial of recurrent C. difficile treatment. Oct 4, 2018 205
PureTech's Vedanta reports successful Phase 1a/1b trial of recurrent C. difficile treatment. Oct 4, 2018 201
Eli Lilly presents phase 2b trial data of dual GIP, GLP-1 receptor agonist. Oct 4, 2018 366
Alnylam reports updated 'positive' results from Phase 1/2 study of lumasiran. Oct 4, 2018 443
Viking Therapeutics: VK2809 Phase 2 study results selected for presentation. Report Oct 4, 2018 172
Ophthotech completes patient recruitment for Phase 2b clinical trial of Zimura. Oct 4, 2018 105
Regenxbio completes dosing fourth cohort in Phase 1 trial of wet AMD candidate. Oct 4, 2018 126
Adamas Pharmaceuticals publishes Phase 3 Gocovri data. Oct 4, 2018 158
Centogene, Denali Therapeutics Team to Recruit LRRK2 Patients for Clinical Trials. Oct 4, 2018 289
Alnylam Submits Clinical Trial Authorization Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease. Oct 4, 2018 437
Vedanta Biosciences Touts Phase 1a/1b Data Demonstrating Safety, Tolerability, and Proof of Mechanism for Lead, Rationally Defined Bacterial Consortium Product Candidate, VE303. Oct 4, 2018 804
Processa Pharmaceuticals wins US FDA clearance to start Phase 2 clinical development of PCS-499 in patients with Necrobiosis Lipoidica. Oct 3, 2018 207
Processa Pharmaceuticals wins US FDA clearance to start Phase 2 clinical development of PCS-499 in patients with Necrobiosis Lipoidica. Oct 3, 2018 203
BioPorto announces initiation of retrospective clinical study with The NGAL Test for children under the age of 18. Clinical report Oct 3, 2018 308
BioPorto announces initiation of retrospective clinical study with The NGAL Test for children under the age of 18. Clinical report Oct 3, 2018 304
Sisi objects to some articles of medical and clinical research draft law. Oct 3, 2018 772
ObsEva reports additional 'positive' Phase 3 results of IMPLANT 2 trial. Oct 3, 2018 211
Al-Sisi expresses objection regarding some articles of clinical trials' draft law. Oct 3, 2018 311
Inotrem demonstrates safety and tolerability of nangibotide in phase IIa study. Oct 2, 2018 159
Inotrem demonstrates safety and tolerability of nangibotide in phase IIa study. Oct 2, 2018 155
Clementia Pharmaceuticals initiates Phase 1 clinical trial of palovarotene. Oct 2, 2018 123
Rexahn presents preliminary data from ongoing Phase 2a trial of RX-3117. Oct 2, 2018 255
Independent Data Monitoring Committee Recommends Continuing Inclisiran Phase III Trials. Oct 2, 2018 347
Aveo Oncology Starts Topline Analysis of Phase 3 TIVO-3 Trial. Oct 2, 2018 800
Seattle Genetics, Takeda Tout Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating Adcetris in Frontline CD30-Expressing Peripheral T-Cell Lymphoma. Oct 2, 2018 1050
Innovent passes US FDA approval to initiate clinical trials of Anti-CD47 Monoclonal Antibody IBI-188. Oct 1, 2018 237
Innovent passes US FDA approval to initiate clinical trials of Anti-CD47 Monoclonal Antibody IBI-188. Oct 1, 2018 233
TransThera Biosciences wins US FDA IND approval for initiating clinical trials of TT-00420 targeting TNBC. Oct 1, 2018 162
TransThera Biosciences wins US FDA IND approval for initiating clinical trials of TT-00420 targeting TNBC. Oct 1, 2018 158
Viking Therapeutics says Phase 2 study of VK5211 achieves primary endpoint. Oct 1, 2018 550

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters